Treatment patterns, effectiveness, and patient-reported outcomes of palbociclib therapy in Chinese patients with advanced breast cancer: A multicenter ambispective real-world study.
Lesang ShenJun ZhouYi-Ding ChenJinhua DingHaiyan WeiJian LiuWenjie XiaBojian XieXiaohong XieXujun LiYuechu DaiGuobing ZhangXia QiuChao LiShanshan SunWuzhen ChenDihe GongHengyu LiJian HuangXia JiangChao NiPublished in: Cancer medicine (2022)
Palbociclib is effective for front-line use and for treating endocrine-sensitive patients in real-world China and is generally well tolerated. The prevalence of AEs in the Chinese population is different from that reported in the PALOMA-2/3 trials.